Weekly Recap | Summit Therapeutics -0.31%, most brokers rate it buy
I'm LongbridgeAI, I can summarize articles.The Week
Summit Therapeutics closed the week at $17.55, down 0.31% from the prior Friday’s close of $17.605. The S&P 500 fell 0.8% over the same period, so the stock outperformed the benchmark by roughly 0.49 percentage points. There were four trading days with an intraweek range of 8.73%. Shares opened Tuesday at $17.43, hit an intraweek high of $18.322 on Wednesday, pulled back to $16.80 on Thursday, then recovered to finish at $17.55 on Friday. The close sits about 4.2% below that Wednesday high, still above the 20-day moving average.
Key Events
The week’s news was concentrated in the first two trading days. Early on September 8, Akeso (9926.HK) rose 6.8% after Ivonescimab topped key cancer rivals in Phase III trials, a development the market linked to Summit Therapeutics’ pipeline positioning. On September 9, Jefferies upgraded Summit Therapeutics to buy, and shares moved higher. The remaining items were largely market-moving briefs and cross-sector signals spanning healthcare, energy, and tech, with limited direct read-through to the company.
Analyst Ratings
As of this week, 17 analysts cover Summit Therapeutics: 10 rate it buy, one rates it outperform, and six rate it hold, with none at underperform or sell. The consensus rating is buy, and the consensus target price is $29.20, around 66.4% above the latest close of $17.55. Targets range from $11.00 to $41.72, showing wide dispersion. The stock ranks 40th by analyst rating within the biotech industry, near the top of a 506-name group.
The Week Ahead
The macro calendar is heavy next week. The New York Fed manufacturing index arrives on September 15, followed on September 16 by multiple US retail sales prints, import prices, the NAHB housing market index, and weekly EIA crude inventory data. For Summit Therapeutics, attention shifts to follow-through from the Ivonescimab trial data and the Jefferies upgrade, as well as sector-level flows across biotech.
In Short
Summit Therapeutics slipped slightly on the week but outperformed the broader market in what was a choppy tape. The rating backdrop leans favourable, with the consensus target well above spot, though the wide target range reflects considerable disagreement. Latest-day capital flow data show large-lot money as a net buyer. The setup for next week hinges on how biotech behaves under a dense macro calendar and whether pipeline news continues to land.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.